Phase I safety, pharmacokinetic, and pharmacogenomic trial of ES-285, a novel marine cytotoxic agent, administered to adult patients with advanced solid tumors

Molecular Cancer Therapeutics

Volumn 8, Issue 6, 2009, Pages 1430-1437

  Baird, Richard D ^a   Kitzen, Jos ^b   Clarke, Paul A ^a   Planting, Andre ^b   Reade, Sarah ^a   Reid, Alison ^a   Welsh, Lyndsey ^a   Lázaro, Luis López ^c   De Las Heras, Begona ^c   Judson, Ian R ^a   Kaye, Stan B ^a   Eskens, Ferry ^b   Workman, Paul ^a   DeBono, Johann S ^a,d   Verweij, Jaap ^b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c PHARMAMAR S A   (Spain)

^d ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC AGENT; ES 285; UNCLASSIFIED DRUG;

ADENOCARCINOMA; ADULT; ADVANCED CANCER; AGED; AMINOTRANSFERASE BLOOD LEVEL; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BLADDER CANCER; CANCER GROWTH; CHONDROSARCOMA; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; ESOPHAGUS CANCER; FATIGUE; FEMALE; FEVER; GENE EXPRESSION; HUMAN; INJECTION SITE REACTION; KIDNEY CANCER; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MELANOMA; MESOTHELIOMA; MULTICENTER STUDY; NAUSEA; NEUROTOXICITY; OSTEOSARCOMA; PANCREAS CANCER; PHARMACOGENOMICS; PHLEBITIS; PRIORITY JOURNAL; PROSTATE CANCER; SIDE EFFECT; SOFT TISSUE SARCOMA; SOLID TUMOR; VOMITING;

ADULT; AGED; ALKANES; ANIMALS; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; BIVALVIA; DOSE-RESPONSE RELATIONSHIP, DRUG; FATIGUE; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INFUSIONS, INTRAVENOUS; LIPIDS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; NAUSEA; NEOPLASMS; TREATMENT OUTCOME; VOMITING; YOUNG ADULT;

EID: 67649342913     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-08-1167     Document Type: Article

References (26)

1. Faircloth G, Cuevas C. Kahalalide F and ES285: potent anticancer agents from marine molluscs. Prog Mol Subcell Biol 2006;43:363-379
2. Weinstein JN, Myers TG, O'Connor PM, et al. An information-intensive approach to the molecular pharmacology of cancer. Science 1997;275:343-349 (Pubitemid 27051604)
3. Baird RD, Clarke PA, Workman P. ES-285, a novel marine anticancer agent: investigation of mechanism of action using gene expression microarrays. Proc Am Assoc Cancer Res 2005;46:Abstract #4111.
4. Cuadros R, Wandosell F, Faircloth G, Fernandez-Sousa JM, Avila J. The marine compound spisulosine, an inhibitor of cell proliferation, promotes the disassembly of actin stress fibers. Cancer Lett 2000;152:23-29 (Pubitemid 30169014)
5. Salcedo M, Cuevas C, Alonso JL, et al. The marine sphingolipid-derived compound ES 285 triggers an atypical cell death pathway. Apoptosis 2007;12:395-409. (Pubitemid 46169919)
6. Sanchez AM, Malagarie-Cazenave S, Olea N, Vara D, Cuevas C, az-Laviada I. Spisulosine (ES-285) induces prostate tumor PC-3 and LNCaP cell death by de novo synthesis ofce ramide and PKCζ activation. Eur J Pharmacol 2008;584:237-245
7. Massard C, Majem M, Soria JC, et al. Phase I (3 hour infusion every 3 weeks) escalating dose study of intravenous ES-285 in patients with advanced malignant solid tumours. Proceedings of AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Meeting 2007; Abstract A4, accessed online 21st June 2008 at http://www.aacr.org/Uploads/DocumentRepository/2007conf/moltar/mt07-postera. pdf.
8. den Brok MW, Nuijen B, Meijer DM, Millan E, Manada C, Beijnen JH. Pharmaceutical development of a parenteral lyophilised formulation of the investigational anticancer agent ES-285.HCl. PDA J Pharm Sci Technol 2005;59:246-257 (Pubitemid 41346134)
9. den Brok MW, Nuijen B, Garcia JL, et al. Compatibility and stability of the novel anticancer agent ES-285x HCl formulated with 2-hydroxypropyl-β- cyclodextrin in infusion devices. Pharmazie 2006;61:21-24 (Pubitemid 43128770)
10. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216
11. Stokvis E, Nan-Offeringa L, Rosing H, et al. Quantitative analysis of ES-285, an investigational marine anticancer drug, in human, mouse, rat, and dog plasma using coupled liquid chromatography and tandem mass spectrometry. J Mass Spectrom 2003;38:548-554 (Pubitemid 36665542)
12. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-159 (Pubitemid 17064313)
13. Van Gelder RN, von Zastrow ME, Yool A, Dement WC, Barchas JD, Eberwine JH. Amplified RNA synthesized from limited quantities of heterogeneous cDNA. Proc Natl Acad Sci U S A 1990;87:1663-1667 (Pubitemid 20098030)
14. Ausubel FM, et al. Current protocols in molecular biology. New York: Greene Publishing Associates and Wiley-Interscience; 2000.
15. Hockley SL, Arlt VM, Brewer D, et al. AHR- and DNA-damage-mediated gene expression responses induced by benzo(a)pyrene in human cell lines. Chem Res Toxicol 2007;20:1797-1810
16. Cleveland WS. Robust locally-weighted regression and smoothing scatterplots. J Am Stat Assoc 1979;74:829-936.
17. Bland JM, Altman DG. Multiple significance tests: the Bonferroni method. BMJ 1995;310:170.
18. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B 1995;57:300.
19. Hosack DA, Dennis G, Jr., Sherman BT, Lane HC, Lempicki RA. Identifying biological themes within lists of genes with EASE. Genome Biol 2003;4:R70.
20. Workman P, Johnston PG. Genomic profiling of cancer: what next? J Clin Oncol 2005;23:7253-7256
21. U.S. Food and Drug Administration. Innovation or Stagnation? Challenge and Opportunity on the Critical Path to New Medicinal Products. FDA 2004.
22. Goodsaid F, Frueh F. Biomarker qualification pilot process at the U.S. Food and Drug Administration. AAPS J 2007;9:E105-8.
23. Workman P. How much gets there and what does it do? The need for better pharmacokinetic and pharmacodynamic endpoints in contemporary drug discovery and development. Curr Pharm Des 2003;9:891-902. (Pubitemid 36367612)
24. Sawyers CL. The cancer biomarker problem. Nature 2008;452:548-552
25. Ratain MJ, Glassman RH. Biomarkers in phase I oncology trials: signal, noise, or expensive distraction? Clin Cancer Res 2007;13:6545-6548
26. Banerji U, de Bono J, Judson I, Kaye S, Workman P. Biomarkers in early clinical trials: the committed and the skeptics. Clin Cancer Res 2008;14:2512. (Pubitemid 351551090)